Clinical characteristics and prognosis of children with T-lineage acute lymphoblastic leukemia: a single-center study

CHEN Xiao-Yan; WANG Jia-Yi; JIANG Hua; ZHANG Wei-Na.

doi:10.7499/j.issn.1008-8830.2408039

PDF(588 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (12) : 1308-1314. DOI: 10.7499/j.issn.1008-8830.2408039

CLINICAL RESEARCH

Clinical characteristics and prognosis of children with T-lineage acute lymphoblastic leukemia: a single-center study

CHEN Xiao-Yan, WANG Jia-Yi, JIANG Hua, ZHANG Wei-Na.

Author information +

History +

Abstract

Objective To study the clinical characteristics and prognosis of T-lineage acute lymphoblastic leukemia (T-ALL) and related prognostic factors. Methods A retrospective analysis was conducted on the children with T-ALL who were treated with the Chinese Children's Cancer Group Acute Lymphoblastic Leukemia (CCCG-ALL) regimen in Guangzhou Women and Children's Medical Center between April 2015 and December 2022. Results A total of 80 children were included, with a median age of 7 years and 3 months and a male/female ratio of 6:1. Among these children, the children with mediastinal mass accounted for 20% (16/80), those with central nervous system leukemia accounted for 4% (3/80), and those with testicular leukemia accounted for 1% (1/69). SIL/TAL1 was the most common fusion gene (22%, 18/80), and NOTCH1 was the most common mutation gene (69%, 37/54). The median follow-up time was 52 months, with a 5-year overall survival (OS) rate of 87.3%±4.0% and a 5-year event-free survival rate of 84.0%±4.3%. The non-central nervous system-1 group had a significantly lower 5-year OS rate than the central nervous system-1 group (66.7%±16.1% vs 90.3%±3.8%; P<0.05), and the group with minimal residual disease (MRD) ≥0.01% on day 46 of induction therapy had a significantly lower 5-year OS rate than the group with MRD <0.01% (68.6%±13.5% vs 94.8%±3.0%; P<0.05). Conclusions Children treated with the CCCG-ALL regimen tend to have a good treatment outcome. Non-central nervous system-1 status and MRD ≥0.01% on day 46 of induction therapy are associated with the poor prognosis in these children.

Key words

Leukemia / T lymphocyte / Prognosis / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CHEN Xiao-Yan, WANG Jia-Yi, JIANG Hua, ZHANG Wei-Na.. Clinical characteristics and prognosis of children with T-lineage acute lymphoblastic leukemia: a single-center study[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(12): 1308-1314 https://doi.org/10.7499/j.issn.1008-8830.2408039

References

1 Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization[J]. J Clin Oncol, 2018, 36(29): 2926-2934. PMID: 30138085. PMCID: PMC6366301. DOI: 10.1200/JCO.2018.77.7250.
2 Cordo' V, van der Zwet JCG, Canté-Barrett K, et al. T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies[J]. Blood Cancer Discov, 2020, 2(1): 19-31. PMID: 34661151. PMCID: PMC8447273. DOI: 10.1158/2643-3230.BCD-20-0093.
3 Yang W, Cai J, Shen S, et al. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial[J]. Lancet Oncol, 2021, 22(9): 1322-1332. PMID: 34329606. PMCID: PMC8416799. DOI: 10.1016/S1470-2045(21)00328-4.
4 Liu X, Zou Y, Zhang L, et al. A novel risk defining system for pediatric T-cell acute lymphoblastic leukemia from CCCG-ALL-2015 group[J]. Front Oncol, 2022, 12: 841179. PMID: 35296004. PMCID: PMC8920043. DOI: 10.3389/fonc.2022.841179.
5 中国抗癌协会小儿肿瘤专业委员会急性淋巴细胞白血病2015多中心研究协作组. CCCG-ALL-2015方案多中心临床报告[J]. 中华儿科杂志, 2022, 60(10): 1002-1010. PMID: 36207846. DOI: 10.3760/cma.j.cn112140-20220719-00895.
6 中国儿童白血病协作组. 中国儿童白血病协作组2018方案治疗儿童急性T淋巴细胞白血病的多中心中期结果总结[J]. 中华儿科杂志, 2023, 61(10): 874-880. PMID: 37803853. DOI: 10.3760/cma.j.cn112140-20230719-00014.
7 Simonin M, Vasseur L, Lengliné E, et al. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients[J]. Blood, 2024, 144(15): 1570-1580. PMID: 38848537. DOI: 10.1182/blood.2023023754.
8 张伟娜, 王鹏飞, 甘文婷, 等. 靶向捕获高深度测序及转录组测序在儿童急性B淋巴细胞白血病中的应用[J]. 白血病·淋巴瘤, 2023, 32(3): 147-152. DOI: 10.3760/cma.j.cn115356-20220413-00108.
9 Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7): 913-920. PMID: 29675840. DOI: 10.1002/ajh.25124.
10 Burns MA, Place AE, Stevenson KE, et al. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001[J]. Pediatr Blood Cancer, 2021, 68(1): e28719. PMID: 33026184. PMCID: PMC8369809. DOI: 10.1002/pbc.28719.
11 Hayashi RJ, Winter SS, Dunsmore KP, et al. Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children's Oncology Group AALL0434[J]. J Clin Oncol, 2020, 38(26): 3062-3070. PMID: 32552472. PMCID: PMC7479761. DOI: 10.1200/JCO.20.00531.
12 Teachey DT, Devidas M, Wood BL, et al. Children's Oncology Group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma[J]. J Clin Oncol, 2022, 40(19): 2106-2118. PMID: 35271306. PMCID: PMC9242409. DOI: 10.1200/JCO.21.02678.
13 Xu J, Zhu HH. Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting[J]. Exp Hematol Oncol, 2023, 12(1): 30. PMID: 36906578. PMCID: PMC10007722. DOI: 10.1186/s40164-023-00384-4.
14 Pui CH, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study[J]. Lancet Oncol, 2015, 16(4): 465-474. PMID: 25800893. PMCID: PMC4612585. DOI: 10.1016/S1470-2045(15)70082-3.
15 Tembhare PR, Narula G, Khanka T, et al. Post-induction measurable residual disease using multicolor flow cytometry is strongly predictive of inferior clinical outcome in the real-life management of childhood T-cell acute lymphoblastic leukemia: a study of 256 patients[J]. Front Oncol, 2020, 10: 577. PMID: 32391267. PMCID: PMC7193086. DOI: 10.3389/fonc.2020.00577.
16 Hayashi RJ, Hermiston ML, Wood BL, et al. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231[J]. Blood, 2024, 143(20): 2053-2058. PMID: 38457359. PMCID: PMC11143515. DOI: 10.1182/blood.2023021184.
17 Petit A, Trinquand A, Chevret S, et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia[J]. Blood, 2018, 131(3): 289-300. PMID: 29051182. DOI: 10.1182/blood-2017-04-778829.
18 Gossai NP, Devidas M, Chen Z, et al. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report[J]. Blood, 2023, 141(15): 1802-1811. PMID: 36603187. PMCID: PMC10122105. DOI: 10.1182/blood.2022018653.